Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial
Publication
, Journal Article
Jolly, S; Mehta, SR; Widimsky, P; Afzal, R; Steg, PG; Valentin, V; Budaj, A; Fox, KAA; Granger, CB; Yusuf, S
Published in: EUROPEAN HEART JOURNAL
September 1, 2007
Duke Scholars
Published In
EUROPEAN HEART JOURNAL
ISSN
0195-668X
Publication Date
September 1, 2007
Volume
28
Start / End Page
516 / 516
Publisher
OXFORD UNIV PRESS
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Jolly, S., Mehta, S. R., Widimsky, P., Afzal, R., Steg, P. G., Valentin, V., … Yusuf, S. (2007). Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial. EUROPEAN HEART JOURNAL, 28, 516–516.
Jolly, S., S. R. Mehta, P. Widimsky, R. Afzal, P. G. Steg, V. Valentin, A. Budaj, K. A. A. Fox, C. B. Granger, and S. Yusuf. “Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.” EUROPEAN HEART JOURNAL 28 (September 1, 2007): 516–516.
Jolly S, Mehta SR, Widimsky P, Afzal R, Steg PG, Valentin V, et al. Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial. EUROPEAN HEART JOURNAL. 2007 Sep 1;28:516–516.
Jolly, S., et al. “Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.” EUROPEAN HEART JOURNAL, vol. 28, OXFORD UNIV PRESS, Sept. 2007, pp. 516–516.
Jolly S, Mehta SR, Widimsky P, Afzal R, Steg PG, Valentin V, Budaj A, Fox KAA, Granger CB, Yusuf S. Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial. EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2007 Sep 1;28:516–516.
Published In
EUROPEAN HEART JOURNAL
ISSN
0195-668X
Publication Date
September 1, 2007
Volume
28
Start / End Page
516 / 516
Publisher
OXFORD UNIV PRESS
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology